Eric Y. Lin
Eric Y. Lin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Cissy M. Tan
Department of Plastic Surgery, Southern California Permanente Medical Group, San Diego, CA 92123, USA
2 shared publications - Elizabeth W. Paxton
Surgical Outcomes and Analysis Department, Kaiser Permanente, San Diego, California
2 shared publications - Jessica E. Harris
Medical Device Surveillance & Assessment, Kaiser Permanente, San Diego, CA 92123, USA
2 shared publications - Robert G. Neumann
Department of Plastic Surgery, The Permanente Medical Group, Santa Rosa, CA 95407, USA
2 shared publications - Tina M. Smith
Department of Plastic Surgery, The Permanente Medical Group, Walnut Creek, CA 94596, USA
2 shared publications - Winnie M. Tong
Department of Plastic Surgery, The Permanente Medical Group, San Francisco, CA 94115, USA
2 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by MDPI AG in Journal of Aesthetic Medicine
- Vol. 2 (2) , 7
The Rate of Return to the Operating Room for Acellular Dermal Matrix (ADM) Versus Non-ADM Direct to Implant Breast Reconstruction: An Economic Analysis for an Integrated Healthcare System
Background/Objectives: Acellular dermal matrix (ADM) is commonly used for breast reconstruction with the proposed benefit of stabilizing the implant pocket and enhancing breast shape. However, some reports highlight safety concerns regarding ADM use. This study evaluates short and long-term unplanned return to the operating room (OR) for immediate implant-based reconstruction with or without ADM. Methods: Females who underwent primary mastectomy with direct to implant reconstruction for breast cancer or risk reduction (2010–2020) were identified using an integrated healthcare system’s EHR. Multivariable Poisson regression was conducted to evaluate return to OR outcomes at early (2 years (IRR = 0.52, 95% CI = 0.29–0.94). Conclusions: The lack of overall difference suggests ADM usage did not impact risk of complications nor improve surgical outcomes. For unilateral cases, ADM is associated with lower rates of return to OR at a higher cost to the healthcare system. Surgeons may use their discretion whether ADM is appropriate for breast reconstruction.
- 1 April 2026
- Published by MDPI AG in Journal of Aesthetic Medicine
- Vol. 2 (2) , 7
Open AccessThe Rate of Return to the Operating Room for Acellular Dermal Matrix (ADM) Versus Non-ADM Direct to Implant Breast Reconstruction: An Economic Analysis for an Integrated Healthcare System
Background/Objectives: Acellular dermal matrix (ADM) is commonly used for breast reconstruction with the proposed benefit of stabilizing the implant pocket and enhancing breast shape. However, some reports highlight safety concerns regarding ADM use. This study evaluates short and long-term unplanned return to the operating room (OR) for immediate implant-based reconstruction with or without ADM. Methods: Females who underwent primary mastectomy with direct to implant reconstruction for breast cancer or risk reduction (2010–2020) were identified using an integrated healthcare system’s EHR. Multivariable Poisson regression was conducted to evaluate return to OR outcomes at early (2 years (IRR = 0.52, 95% CI = 0.29–0.94). Conclusions: The lack of overall difference suggests ADM usage did not impact risk of complications nor improve surgical outcomes. For unilateral cases, ADM is associated with lower rates of return to OR at a higher cost to the healthcare system. Surgeons may use their discretion whether ADM is appropriate for breast reconstruction.
- Open Access
Assessing First and Multiple Reoperations in 23,301 Breast Reconstructions: Immediate Versus Delayed Reconstructions in Women with Breast Cancer
Background: Few studies have compared the risk of reoperation by timing in breast reconstruction surgery after mastectomy. We evaluated the first and total number of reoperations by reconstruction timing in women with breast cancer undergoing primary mastectomy. Methods: A cohort study of 23,301 primary mastectomies in women with breast cancer undergoing either immediate breast reconstruction (IBR) or delayed reconstruction was carried out within Kaiser Permanente between 2010 and 2022. The first reoperation rate was calculated using cause-specific Cox Proportional Hazards Models, while Multiplicative Cox Proportional Hazards Models were used to account for mortality and timing in reoperation. Patients were continuously monitored for death, outcome of interest, loss to follow-up through healthcare membership termination, or study end date (31 December 2022). Results: In total, 78.4% (n = 18,276) of the cohort underwent IBR. The average follow-up time was 5.9 years (±3.8). The following covariates were imbalanced (standardized mean difference [SMD] ≥ 0.20) between IBR and delayed groups: BMI, smoking status, year of mastectomy, bilateral procedures, and reconstruction type. The crude incidence of first reoperation was 33.04% vs. 31.72% in IBR vs. delayed patients and the risk of reoperation was 18% higher in IBR patients (HR = 1.18, 95% CI = 1.12–1.25). There was no difference in the risk of reoperation by timing (p > 0.05) when assessing multiple reoperations. The reoperation risk was the highest for IBR patients who did not complete reconstruction or single-stage reconstruction. In addition, the first reoperation rate of IBR patients was higher in those who underwent expander–implant-based reconstruction. Conclusions: The first reoperation rate was higher in IBR patients compared to those who delayed reconstruction, although we failed to detect a difference for multiple returns to surgery, except in certain subgroups. Assessing reoperation risk by timing among different reconstruction modalities can aid patients in making informed decisions about the type of breast reconstruction to undergo.
Open AccessAssessing First and Multiple Reoperations in 23,301 Breast Reconstructions: Immediate Versus Delayed Reconstructions in Women with Breast Cancer
Background: Few studies have compared the risk of reoperation by timing in breast reconstruction surgery after mastectomy. We evaluated the first and total number of reoperations by reconstruction timing in women with breast cancer undergoing primary mastectomy. Methods: A cohort study of 23,301 primary mastectomies in women with breast cancer undergoing either immediate breast reconstruction (IBR) or delayed reconstruction was carried out within Kaiser Permanente between 2010 and 2022. The first reoperation rate was calculated using cause-specific Cox Proportional Hazards Models, while Multiplicative Cox Proportional Hazards Models were used to account for mortality and timing in reoperation. Patients were continuously monitored for death, outcome of interest, loss to follow-up through healthcare membership termination, or study end date (31 December 2022). Results: In total, 78.4% (n = 18,276) of the cohort underwent IBR. The average follow-up time was 5.9 years (±3.8). The following covariates were imbalanced (standardized mean difference [SMD] ≥ 0.20) between IBR and delayed groups: BMI, smoking status, year of mastectomy, bilateral procedures, and reconstruction type. The crude incidence of first reoperation was 33.04% vs. 31.72% in IBR vs. delayed patients and the risk of reoperation was 18% higher in IBR patients (HR = 1.18, 95% CI = 1.12–1.25). There was no difference in the risk of reoperation by timing (p > 0.05) when assessing multiple reoperations. The reoperation risk was the highest for IBR patients who did not complete reconstruction or single-stage reconstruction. In addition, the first reoperation rate of IBR patients was higher in those who underwent expander–implant-based reconstruction. Conclusions: The first reoperation rate was higher in IBR patients compared to those who delayed reconstruction, although we failed to detect a difference for multiple returns to surgery, except in certain subgroups. Assessing reoperation risk by timing among different reconstruction modalities can aid patients in making informed decisions about the type of breast reconstruction to undergo.